Featured Research

from universities, journals, and other organizations

New Risks For Bladder Cancer Identified By MIT Team

Date:
October 8, 2004
Source:
Massachusetts Institute Of Technology
Summary:
MIT researchers and colleagues have identified three new chemical risk factors for bladder cancer in a study involving some 600 people in the Los Angeles area.

From left, Pete Wishok, Paul Skipper and Steve Tannenbaum, display diagrams related to their work identifying three new chemical risk factors for bladder cancer.
Credit: Photo Donna Coveney

MIT researchers and colleagues have identified three new chemical risk factors for bladder cancer in a study involving some 600 people in the Los Angeles area. The work was reported in the Oct. 6 issue of the Journal of the National Cancer Institute.

The newly discovered carcinogens are found in cigarette smoke, which is already known to be a major cause of bladder cancer, contributing to at least 50 percent of the approximately 60,000 cases in the United States every year.

All three of the new carcinogens, however, were also found to be risk factors for bladder cancer in nonsmokers. Although second-hand smoke is one source of exposure for non-smokers, the researchers say that it is very important to identify the other sources of exposure for nonsmokers.

"Identifying the non-smoking related sources of these [carcinogens] should become a high scientific priority," write the authors, who are led by Professor Steven R. Tannenbaum, the Underwood-Prescott Professor of Toxicology at MIT.

"This is very important from a public health point of view," said Tannenbaum, who holds appointments in the Biological Engineering (BE) Division and the Department of Chemistry. "It's much more effective to prevent cancer rather than treat it."

The team also identified six chemicals in the same chemical family that do not appear to be human carcinogens. Because they are chemically similar to their three noxious cousins, they could potentially lead to safer alternatives for the latter.

Authors of the paper from MIT are Tannenbaum, Paul L. Skipper, a BE principal research scientist, and Jinping Gan, a former graduate student. Their colleagues Manuela Gago-Dominguez, Kazuko Arakawa, Ronald K. Ross, and Mimi C. Yu are at the University of Southern California, Los Angeles.

In 1993 Tannenbaum and Skipper teamed up with Yu on the ongoing Los Angeles Bladder Cancer Study. Among other conclusions, that study has since identified a compound in the arylamine family that is a risk factor for bladder cancer in nonsmokers.

In the current work, the researchers extended the Los Angeles study to examine "the possible relationship between bladder cancer … and nine other commonly occurring and structurally related arylamines," according to their paper.

Specifically, they analyzed blood samples from some 600 of the people involved in the study. Half had bladder cancer; the others did not but were matched against their counterparts for such things as age, sex and neighborhood.

The team then measured exposure to the arylamines via a technique developed by Tannenbaum's team more than 25 years ago. Arylamines to which a person is exposed react with a protein in the blood, resulting in specific products that can be detected and measured via mass spectrometry.

"So what popped out of this was actually pretty startling," Tannenbaum said. "Three of the nine compounds were indeed found to be significant risk factors for bladder cancer in nonsmokers. And except for one, none of those nine had ever been investigated before" for their potential carcinogenic activity, Tannenbaum said.

This work was sponsored by the National Institutes of Health through the National Cancer Institute and the National Institute of Environmental Health Sciences.


Story Source:

The above story is based on materials provided by Massachusetts Institute Of Technology. Note: Materials may be edited for content and length.


Cite This Page:

Massachusetts Institute Of Technology. "New Risks For Bladder Cancer Identified By MIT Team." ScienceDaily. ScienceDaily, 8 October 2004. <www.sciencedaily.com/releases/2004/10/041008023311.htm>.
Massachusetts Institute Of Technology. (2004, October 8). New Risks For Bladder Cancer Identified By MIT Team. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2004/10/041008023311.htm
Massachusetts Institute Of Technology. "New Risks For Bladder Cancer Identified By MIT Team." ScienceDaily. www.sciencedaily.com/releases/2004/10/041008023311.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins